Inhibition of lipoprotein secretion

Details Inhibition of lipoprotein secretion Inhibition of lipoprotein secretion

A - Human Necessities

61

K

A61K 38/17 (2006.01) A61K 48/00 (2006.01)

Patent

CA 2416793

It has been discovered that the low density lipoprotein receptor (LDLR) degrades the lipoprotein apoB. Based on this observation, an artificial fusion protein has been designed containing an LDL receptor domain attached to a localization domain which causes retention of the fusion protein inside of a cell. The fusion protein is preferably retained in the endoplasmic reticulum of the cell, where the LDLR can degrade apoB. Data shows that the technique is effective in a mammal to reduce serum LDL cholesterol levels.

On a découvert que le récepteur de la lipoprotéine basse densité (LDLR) dégrade la lipoprotéine apoB. Partant, on a conçu une protéine de fusion artificielle renfermant un domaine récepteur LDL attaché à un domaine de localisation qui provoque une rétention de la protéine de fusion à l'intérieur de la cellule. Cette protéine de fusion est de préférence retenue dans le réticulum endoplasmique de la cellule, là où la lipoprotéine basse densité peut dégrader la lipoprotéine apoB. Cette technique s'avère efficace pour réduire les taux de cholestérol LDL sérique.

Affiliated with

Also associated with

Rating

Inhibition of lipoprotein secretion does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Inhibition of lipoprotein secretion, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibition of lipoprotein secretion will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-2050759